US launches trade probe into Germany over drug pricing

Email: online@newsofbahrain.com

The US has opened a formal trade investigation into Germany's pharmaceutical pricing structure, saying that the country's regulations unlawfully undervalue innovative medicines manufactured by American companies. The investigation, launched under Section 301 of the US Trade Act of 1974, will look at whether Germany's pricing and reimbursement procedures discriminate against US drug makers and impose an unreasonable financial burden on American consumers.

US Trade Representative Jamieson Greer argues that Germany's healthcare system artificially lowers drug prices through government-controlled negotiations and reimbursement restrictions. According to Washington, these regulations force pharmaceutical companies to accept much cheaper costs for new pharmaceuticals in Germany, while US patients face a disproportionate portion of the global cost of research and development.

The decision comes as Germany examines healthcare reforms aimed at reducing public spending on drugs. US officials have expressed concern that the proposed reforms will further tighten pricing controls and cut funding for new drugs. The pharmaceutical industry has consistently argued that European pricing regulations limit returns on investment and hinder innovation, while governments defend the laws as vital to make healthcare affordable.

If the investigation finds that Germany's policies are unjustified or discriminatory, the United States may take reciprocal action, including taxes on German products. The investigation is likely to heighten tensions in US-German trade relations and expand debates on medication pricing, healthcare expenditures, and intellectual property safeguards on both sides of the Atlantic.